Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports

09-04-2024 | Breast Cancer | Review

Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life

Authors: Ellie M. Proussaloglou, Maryam B. Lustberg

Published in: Current Breast Cancer Reports

Login to get access

Abstract

Purpose of Review

Young patients with breast cancer have unique survivorship needs, including fertility and family planning concerns, complications from iatrogenic menopause, and long-term quality-of-life issues. We aim to summarize the latest data on these side effects of cancer care to guide physicians in providing evidence-based survivorship care for this unique group of patients.

Recent Findings

Fertility preservation is safe prior to cancer treatment without any adverse impact on disease-free recurrence or overall survival. Pregnancy after breast cancer can be achieved safely; preliminary data from the POSITIVE trial suggest that endocrine therapy can be safely paused to allow for conception prior to age-related declines in fertility.

Summary

Additional research will help us understand controversial topics in survivorship care for young breast cancer patients including safe and effective contraception, use of vaginal estrogen for severe genitourinary syndrome of menopause and pausing anti-estrogen therapy to allow for safe conception, pregnancy, and post-partum care.
Literature
1.
Dobi Á, Kelemen G, Kaizer L, Weiczner R, Thurzó L, Kahán Z. Breast cancer under 40 years of age: increasing number and worse prognosis. Pathol Oncol Res. 2011;17(2):425–8.PubMedCrossRef
2.
• Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA, Bianchi-Micheli G, et al. ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). Ann Oncol. 2022;33(11):1097–118. Most recent guidelines from the European Society of Medical Oncology reviewing evidence-based recommendations for treatment of breast cancer in young women, along with population-specific survivorship care and concerns.PubMedCrossRef
3.
Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. CA A cancer J Clin. 2022;72(6):524–41.CrossRef
4.
DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA A Cancer J Clin. 2017;67(6):439–48.CrossRef
5.
6.
Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE. 2009;4(11):e7695.PubMedPubMedCentralCrossRef
7.
Bharat A, Aft RL, Gao F, Margenthaler JA. Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. J Surg Oncol. 2009;100(3):248–51.PubMedCrossRef
8.
Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34(27):3308–14.PubMedCrossRef
9.
Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg JB, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†. Ann Oncol. 2020;31(12):1664–78.PubMedCrossRef
10.
Jacobson MH, Mertens AC, Spencer JB, Manatunga AK, Howards PP. Menses resumption after cancer treatment–induced amenorrhea occurs early or not at all. Fertil Steril. 2016;105(3):765–724.PubMedCrossRef
11.
Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat. 2009;113(2):315–20.PubMedCrossRef
12.
Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423–38.PubMedCrossRef
13.
Lambertini M, Horicks F, Del Mastro L, Partridge AH, Demeestere I. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical application. Cancer Treat Rev. 2019;72:65–77.PubMedCrossRef
14.
Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018;36(19):1981–90.PubMedPubMedCentralCrossRef
15.
Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update. 2001;7(4):394–403.PubMedCrossRef
16.
Silverstein J, Post AL, Chien AJ, Olin R, Tsai KK, Ngo Z, et al. Multidisciplinary management of cancer during pregnancy. JCO Oncology Practice. 2020;16(9):545–57.PubMedCrossRef
17.
Lambertini M, Marrocco C, Spinaci S, Demeestere I, Anderson RA. Risk of gonadotoxicity with immunotherapy and targeted agents remains an unsolved but crucial issue. Eur J Clin Invest. 2022;52(7):e13779.PubMedCrossRef
18.
Winship AL, Griffiths M, Lliberos Requesens C, Sarma U, Phillips K-A, Hutt KJ. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. Hum Reprod. 2020;35(8):1864–74.PubMedCrossRef
19.
Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001.PubMedCrossRef
20.
Razeti MG, Soldato D, Arecco L, Levaggi A, Puglisi S, Solinas C, et al. Approaches to fertility preservation for young women with breast cancer. Clin Breast Cancer. 2023;23(3):241–8.PubMedCrossRef
21.
Rosenberg E, Fredriksson A, Einbeigi Z, Bergh C, Strandell A. No increased risk of relapse of breast cancer for women who give birth after assisted conception. Hum Reprod Open. 2019;2019(4):hoz039.PubMedPubMedCentralCrossRef
22.
Fredriksson A, Rosenberg E, Einbeigi Z, Bergh C, Strandell A. Gonadotrophin stimulation and risk of relapse in breast cancer. Hum Reprod Open. 2021;2021(1):hoaa061.PubMedPubMedCentralCrossRef
23.
Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab. 2016;101(4):1364–71.PubMedPubMedCentralCrossRef
24.
Arecco L, Blondeaux E, Bruzzone M, Ceppi M, Latocca MM, Marrocco C, et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum Reprod. 2022;37(5):954–68.PubMedPubMedCentralCrossRef
25.
Korkidakis A, Lajkosz K, Green M, Strobino D, Velez MP. Patterns of referral for fertility preservation among female adolescents and young adults with breast cancer: a population-based study. J Adolesc Young Adult Oncol. 2019;8(2):197–204.PubMedPubMedCentralCrossRef
26.
Warner E, Yee S, Kennedy E, Glass K, Foong S, Seminsky M, et al. Oncofertility knowledge, attitudes, and practices of Canadian breast surgeons. Ann Surg Oncol. 2016;23(12):3850–9.PubMedCrossRef
27.
Bastings L, Baysal O, Beerendonk CC, Braat DD, Nelen WL. Referral for fertility preservation counselling in female cancer patients. Hum Reprod. 2014;29(10):2228–37.PubMedCrossRef
28.
29.
Dorfman CS, Stalls JM, Mills C, Voelkel S, Thompson M, Acharya KS, et al. Addressing barriers to fertility preservation for cancer patients: the role of oncofertility patient navigation. J Oncol Navig Surviv. 2021;12(10):332–48.PubMedPubMedCentral
30.
Sauerbrun-Cutler MT, Pandya S, Recabo O, Raker C, Clark MA, Robison K. Survey of young women with breast cancer to identify rates of fertility preservation (FP) discussion and barriers to FP care. J Assist Reprod Genet. 2023;40(8):2003–11.PubMedCrossRef
31.
American College of Obstetricians and Gynecologists’ committee on Clinical Consensus-Obstetrics. Pregnancy at age 35 years or older: ACOG obstetric care consensus no. 11. Obstet Gynecol. 2022;140(2):348–66.
32.
Ruddy KJ, Gelber SI, Tamimi RM, Ginsburg ES, Schapira L, Come SE, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32(11):1151–6.PubMedPubMedCentralCrossRef
33.
Lambertini M, Blondeaux E, Bruzzone M, Perachino M, Anderson RA, de Azambuja E, et al. Pregnancy after breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2021;39(29):3293–305.PubMedCrossRef
34.
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, et al. Who are the women who enrolled in the POSITIVE trial: a global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast. 2021;59:327–38.PubMedPubMedCentralCrossRef
35.
• Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645–56. This groundbreaking study assessed the safety of interrupting endocrine therapy for patients with ER/PR+ breast cancer to allow for conception and pregnancy. Three-year incidence of breast cancer was similar between the study population and controls continuing on their therapy with > 70% of patients becoming pregnant.PubMedPubMedCentralCrossRef
36.
Moreno PI, Esquives BN, Thomas JL, Horner FS, Torzewski JB, Gradishar W, et al. Characterizing unique supportive care needs among women living with metastatic breast cancer: a qualitative study. J Psychosoc Oncol Res Pract. 2023;5(1).
37.
Castro-Sanchez A, Martinez-Cannon BA, Platas A, Mohar A, Fonseca A, Vega Y, et al. Suboptimal use of effective contraceptive methods in young Mexican women with breast cancer. J Glob Oncol. 2018;4:1–7.PubMed
38.
Kopeika J, Bhaduri M, Kugadas A, Reddy N, Shewbridge A, Mukherji D, et al. Planned and unplanned pregnancies in breast cancer survivors. Breast (Edinburgh, Scotland). 2019;46:75–80.PubMedCrossRef
39.
40.
Hadnott TN, Stark SS, Medica A, Dietz AC, Martinez ME, Whitcomb BW, et al. Perceived infertility and contraceptive use in the female, reproductive-age cancer survivor. Fertil Steril. 2019;111(4):763–71.PubMedPubMedCentralCrossRef
41.
Lambertini M, Massarotti C, Havas J, Pistilli B, Martin AL, Jacquet A, et al. Contraceptive use in premenopausal women with early breast cancer. JAMA Netw Open. 2022;5(9):e2233137.PubMedPubMedCentralCrossRef
42.
Fu Y, Zhuang Z. Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis. Int J Clin Exp Pathol. 2014;7(10):6419–29.PubMedPubMedCentral
43.
Practice Bulletin No. 186: Long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2017;130(5):e251–69.
44.
Kwait RM, Pesek S, Onstad M, Edmonson D, Clark MA, Raker C, et al. Influential forces in breast cancer surgical decision making and the impact on body image and sexual function. Ann Surg Oncol. 2016;23(10):3403–11.PubMedCrossRef
45.
Åsberg RE, Giskeødegård GF, Raj SX, Karlsen J, Engstrøm M, Salvesen Ø, et al. Sexual functioning, sexual enjoyment, and body image in Norwegian breast cancer survivors: a 12-year longitudinal follow-up study and comparison with the general female population. Acta Oncol. 2023;62(7):719–27.PubMedCrossRef
46.
Chang CP, Ho TF, Snyder J, Dodson M, Deshmukh V, Newman M, et al. Breast cancer survivorship and sexual dysfunction: a population-based cohort study. Breast Cancer Res Treat. 2023;200(1):103–13.PubMedCrossRef
47.
Blouet A, Zinger M, Capitain O, Landry S, Bourgeois H, Seegers VT, et al. Sexual quality of life evaluation after treatment among women with breast cancer under 35 years old. Support Care Cancer. 2019;27(3):879–85.PubMedCrossRef
48.
Soldera SV, Ennis M, Lohmann AE, Goodwin PJ. Sexual health in long-term breast cancer survivors. Breast Cancer Res Treat. 2018;172(1):159–66.PubMedCrossRef
49.
Smedsland SK, Vandraas KF, Falk RS, Horn J, Reidunsdatter RJ, Kiserud CE, et al. Sexual health in long-term breast cancer survivors: a comparison with female population controls from the HUNT study. Breast Cancer Res Treat. 2023;201(3):479–88.PubMedPubMedCentralCrossRef
50.
Huynh V, Vemuru S, Hampanda K, Pettigrew J, Fasano M, Coons HL, et al. No one-size-fits-all: sexual health education preferences in patients with breast cancer. Ann Surg Oncol. 2022;29(10):6238–51.PubMedPubMedCentralCrossRef
51.
Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus. Obstetrics and gynecology. 2021;138(6):950–60.
52.
Rojas K, Spring LM, O'Riordan L, Weiss A. Endocrine therapy for surgeons: practical pearls for managing menopausal, bone loss and sexual adverse effects. Ann Surg Oncol. 2023;30(10):5951–5961.
53.
The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of the North American menopause society. Menopause. 2020;27(9):976–92.
54.
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–68.
55.
Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022;114(10):1347–54.PubMedPubMedCentralCrossRef
56.
Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract. 2012;8(3):144–8.PubMedPubMedCentralCrossRef
57.
Barton DL, Sloan JA, Shuster LT, Gill P, Griffin P, Flynn K, et al. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer. 2018;26(2):643–50.PubMedCrossRef
58.
Carter J, Lacchetti C, Andersen BL, Barton DL, Bolte S, Damast S, et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology clinical practice guideline adaptation of Cancer Care Ontario Guideline. J Clin Oncol. 2018;36(5):492–511.PubMedCrossRef
59.
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122–37.PubMedPubMedCentralCrossRef
60.
Satish S, Pon F, Calfa CJ, Perez AT, Rojas KE. Characterizing genitourinary exam disruptions in women presenting to a sexual health after cancer program. J Clin Oncol. 2022;40(16_suppl):e24048-e.CrossRef
61.
Hutton B, Hersi M, Cheng W, Pratt M, Barbeau P, Mazzarello S, et al. Comparing interventions for management of hot flashes in patients with breast and prostate cancer: a systematic review with meta-analyses. Oncol Nurs Forum. 2020;47(4):E86-e106.PubMedPubMedCentral
62.
Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–37.PubMedCrossRef
63.
Dibble KE, Baumgartner RN, Boone SD, Baumgartner KB, Connor AE. Treatment-related side effects among Hispanic and non-Hispanic white long-term breast cancer survivors by tamoxifen use and duration. Breast Cancer Res Treat. 2023;199(1):155–72.PubMedPubMedCentralCrossRef
64.
Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski RT, Curigliano G, et al. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Ann Oncol. 2022;33(11):1119–33.PubMedCrossRef
65.
Fernandes-Taylor S, Adesoye T, Bloom JR. Managing psychosocial issues faced by young women with breast cancer at the time of diagnosis and during active treatment. Curr Opin Support Palliat Care. 2015;9(3):279.PubMedPubMedCentralCrossRef
66.
Neamţiu L, Deandrea S, Pylkkänen L, Freeman C, López Alcalde J, Bramesfeld A, et al. Psycho-oncological support for breast cancer patients: a brief overview of breast cancer services certification schemes and national health policies in Europe. Breast (Edinburgh, Scotland). 2016;29:178–80.PubMedCrossRef
67.
Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019;37(31):2916–46.PubMedCrossRef
68.
Lee J, Alqudaihi HM, Kang MS, Kim J, Lee JW, Ko BS, et al. Effect of tamoxifen on the risk of osteoporosis and osteoporotic fracture in younger breast cancer survivors: a nationwide study. Front Oncol. 2020;10:366.PubMedPubMedCentralCrossRef
69.
Joaquim A, Amarelo A, Antunes P, Garcia C, Leão I, Vilela E, et al. Effects of a physical exercise program on quality of life and physical fitness of breast cancer survivors: the MAMA_MOVE Gaia after treatment trial. Psychol Health Med. 2023:1–24.
70.
Schröder CP, van Leeuwen-Stok E, Cardoso F, Linderholm B, Poncet C, Wolff AC, et al. Quality of life in male breast cancer: prospective study of the international male breast cancer program (EORTC10085/TBCRC029/BIG2–07/NABCG). Oncologist. 2023;28(10):e877–e883.
Metadata
Title
Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life
Authors
Ellie M. Proussaloglou
Maryam B. Lustberg
Publication date
09-04-2024
Publisher
Springer US
Published in
Current Breast Cancer Reports
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-024-00548-z
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits